CDK
Les inhibiteurs des kinases dépendantes des cyclines (CDK) sont des composés qui bloquent l'activité des CDK, un groupe de kinases protéiques qui régulent le cycle cellulaire, la transcription et d'autres processus cellulaires. Les CDK sont activées par leur liaison aux cyclines, et leur activité est cruciale pour la progression des cellules à travers les différentes phases du cycle cellulaire. Inhiber les CDK peut arrêter la division cellulaire, entraînant un arrêt du cycle cellulaire et l'apoptose, en particulier dans les cellules cancéreuses où les CDK sont souvent dysrégulées. Les inhibiteurs de CDK sont largement utilisés dans la recherche sur le cancer et ont un potentiel thérapeutique dans le traitement de divers cancers. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de CDK de haute qualité pour soutenir vos recherches sur le contrôle du cycle cellulaire, le cancer et le développement thérapeutique.
577 produits trouvés pour "CDK".
Filtrer par
Pourcentage de pureté
0
100
|
0
|
50
|
90
|
95
|
100
- Tri par prix ascendant
- Tri par prix descendant
- Puretés inférieures
- Puretés supérieures
- Livraison estimée la plus rapide
JH-XVI-178
CAS :JH-XVI-178: potent CDK8/19 inhibitor with good pharmacokinetics, low clearance, moderate oral bioavailability.Formule :C22H22ClN7OCouleur et forme :SolidMasse moléculaire :435.909EGFR/CDK2-IN-3
EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58PROTAC CDK9 degrader-8
PROTAC CDK9 Degrader-8 (Compound 21) is a potent degrader of CDK9 with an IC50 of 0.01 μM, utilized in cancer research [1].Formule :C44H52Cl2N10O7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :903.85EGFR/CDK2-IN-2
EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99Multi-target kinase inhibitor 2
Compound 5K (Multi-target kinase inhibitor 2) is a multi-targeted kinase inhibitor demonstrating activity against EGFR, Her2, VEGFR2, and CDK2 with IC50 valuesDegré de pureté :98%Couleur et forme :Odour SolidSNX7
CAS :SNX7 (WAY-323879) inhibits CDKI pathway; useful for studying aging and related diseases.Formule :C15H14N2ODegré de pureté :99.96%Couleur et forme :SolidMasse moléculaire :238.2845FDA-Approved Kinase Inhibitor Library
A unique collection of xnum kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.Couleur et forme :LiquidCell Cycle Compound Library
A unique collection of xnum cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS);Couleur et forme :Odour SolidPROTAC CDK2/4 Degrader-1
CAS :PROTACCDK2/4 Degrader-1 (Compound 5) is a potent CDK2/4 PROTAC degrader with a DC50 of ≤ 10 nM for both CDK2 and CDK4. It demonstrates excellent activity in inhibiting cell proliferation in OVCAR3 and T47D cell lines. This compound is applicable for breast cancer and ovarian cancer research.Formule :C31H40F2N8O5SMasse moléculaire :674.77PROTAC D16-M1P2
PROTACD16-M1P2 is an orally active PKMYT1 PROTAC degrader with a DC50 of 0.7 nM. It also exhibits inhibitory activity against PKMYT1 with an IC50 of 7.6 nM and inhibits pCDK1 with an IC50 of 9 nM. PROTACD16-M1P2 demonstrates significant antitumor activity in mouse models and is applicable for breast cancer research.DN1679
DN1679 is a potent, selective, and orally active CRBN-dependent dual degrader of CDK12/13 PROTAC. It exhibits DC50 values for CDK12/13 at 8.8/9.8 nM in MDA-MB-231 cells, 5.1/6.4 nM in MDA-MB-157 cells, and 17.2/15.8 nM in MDA-MB-468 cells. DN1679 downregulates mRNA levels of DNA damage response genes such as ATM, ATR, BRCA1, and RAD51. When used in combination with Olaparib, DN1679 shows a significant synergistic anti-tumor effect. It is applicable in research on triple-negative breast cancer.CDK4/6-IN-5
CAS :CDK4/6-IN-5 inhibits CDK4/6; Ki: 0.2 nM (CDK4/D1) & 4.4 nM (CDK6/D3). (WO2019207463A1, A93)Formule :C22H28ClFN6O4SCouleur et forme :SolidMasse moléculaire :527.01CDK9 inhibitor HH1
CAS :CDK9 inhibitor HH1 (8019-9719) is an inhibitor of the human CDK2-cyclin A2 complex with an IC50 value of 2 μM.Formule :C13H15N3OSDegré de pureté :99.92%Couleur et forme :SolidMasse moléculaire :261.343CDK2/PIM1-IN-1
CDK2/PIM1-IN-1 is an inhibitor of the kinases CDK2 (IC50: 0.27 μM) and PIM1 (IC50: 0.67 μM). It can induce apoptosis (cell death) and reduce the expression of TNF-α, which promotes tumors. CDK2/PIM1-IN-1 exhibits antitumor activity.Couleur et forme :Odour SolidLO-3-63
LO-3-63 is a Ribociclib analogue featuring a truncated fumaramide group and acts as a CDK4/6 degrader with PROTAC properties. It degrades CDK4/6 in cells via a CUL4DCAF16-dependent pathway.Couleur et forme :Odour SolidKB-0742 hydrochloride
KB-0742 hydrochloride is a potent, selective, and orally active CDK9 inhibitor, with an IC50 of 6 nM for CDK9/cyclin T1. It exhibits over 50 times selectivity towards CDK9/cyclin T1 compared to other CDK kinases. Additionally, KB-0742 hydrochloride demonstrates effective antitumor activity.BSJ-03-204
CAS :BSJ-03-204 is a selective Cdk4/6 degrader.Formule :C43H48N10O8Couleur et forme :SolidMasse moléculaire :832.9JH-XI-10-02
CAS :JH-XI-10-02 selectively degrades CDK8 (IC50: 159 nM) through proteasome, sparing CDK8 mRNA and CDK19.Formule :C53H69N5O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :920.161CDK4/6-IN-15 hydrochloride
CDK4/6-IN-15 hydrochloride is an orally active selective inhibitor of CDK4/6. It effectively restrains the growth of cancer cells by arresting the cell cycle at the G1 phase. Additionally, CDK4/6-IN-15 hydrochloride inhibits phosphorylation of the retinoblastoma tumor suppressor protein (Rb) at site S780 and suppresses E2 factor (E2F)-regulated gene expression.Formule :C21H28ClFN8SMasse moléculaire :478.18302CDK7-IN-7
CAS :CDK7-IN-7: Selective CDK7 inhibitor, IC50 < 50 nM (Patent CN112661745A).Formule :C20H20BrF3N6O2Couleur et forme :SolidMasse moléculaire :513.319
